Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigation of Tolerability, Safety, and Pharmacokinetic Properties of a Single Oral Dose of Monlunabant in Male Japanese and Caucasian Participants With Normal Body Weight

NCT06542536 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT06542536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06542536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigation of Tolerability, Safety, and Pharmacokinetic Properties of a Single Oral Dose of Monlunabant in Male Japanese and Caucasian Participants With Normal Body Weight
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Completed
Start date
August 9, 2024
Completion date
October 25, 2024
Enrollment
73 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity